Surgical and Perioperative Treatments for Esophagogastric Junction Cancer
Y Yanagimoto, Y Kurokawa, Y Doki - Annals of Thoracic and …, 2024 - jstage.jst.go.jp
Esophagogastric junction cancer (EGJC) is a rare malignant disease that occurs in the
gastroesophageal transition zone. In recent years, its incidence has been rapidly increasing …
gastroesophageal transition zone. In recent years, its incidence has been rapidly increasing …
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive …
M Tokunaga, N Machida, J Mizusawa, S Ito… - Gastric Cancer, 2024 - Springer
Background This randomized phase II study explored the superiority of trastuzumab plus S-1
plus cisplatin (SP) over SP alone as neoadjuvant chemotherapy (NAC) for HER2-positive …
plus cisplatin (SP) over SP alone as neoadjuvant chemotherapy (NAC) for HER2-positive …
[HTML][HTML] Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the …
I Nakayama, M Ohashi, S Nunobe - Chinese Clinical Oncology, 2024 - cco.amegroups.org
The survival outcome of patients with locally advanced gastric or gastroesophageal junction
(G/GEJ) cancer remains unsatisfactory, and improvements in survival and recurrence remain …
(G/GEJ) cancer remains unsatisfactory, and improvements in survival and recurrence remain …
Comparison of Survival Between ypStage and pStage in Gastric Cancer
K Komori, T Yamada, S Ando, I Hashimoto… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: In East Asia, the standard treatment for resectable advanced gastric
cancer involves gastrectomy and postoperative adjuvant chemotherapy; nevertheless …
cancer involves gastrectomy and postoperative adjuvant chemotherapy; nevertheless …